NPC(SH:600713)2024-04-29 07:41Financial Performance - The company's operating revenue for Q1 2024 was CNY 13,952,545,044.79, representing a decrease of 0.92% compared to the same period last year[4]. - Net profit attributable to shareholders of the listed company was CNY 159,082,706.83, an increase of 6.65% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 154,339,574.01, reflecting a growth of 3.24% compared to the previous year[5]. - The basic earnings per share for the period was CNY 0.123, up by 7.89% year-on-year[5]. - Net profit for Q1 2024 reached CNY 196,947,119.74, an increase of 7.3% compared to CNY 183,605,107.97 in Q1 2023[31]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.123, up from CNY 0.114 in Q1 2023, reflecting a growth of 7.9%[32]. - The total comprehensive income for Q1 2024 was CNY 190,717,511.66, down from CNY 201,093,566.48 in Q1 2023[32]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 32,563,722,934.32, an increase of 14.62% from the end of the previous year[5]. - The company's total liabilities reached RMB 25.11 billion, up from RMB 21.16 billion, indicating a rise of about 18.5%[29]. - Total assets as of March 31, 2024, amounted to CNY 16,914,189,581.34, an increase from CNY 14,097,197,729.67 at the end of 2023[38]. - The total assets increased to CNY 19,314,597,869.52 in Q1 2024, up from CNY 16,175,490,721.71 in Q1 2023, reflecting a growth of 13.2%[39]. - The total liabilities rose to CNY 14,004,965,188.09 in Q1 2024, compared to CNY 10,888,031,729.77 in Q1 2023, marking an increase of 28.9%[39]. Cash Flow and Financing - Cash flow from operating activities showed a net outflow of CNY -3,893,131,191.42, compared to CNY -3,456,016,751.84 in Q1 2023[34]. - The cash flow from operating activities showed a net outflow of CNY 828,409,382.23 in Q1 2024, an improvement from the outflow of CNY 1,169,978,140.52 in Q1 2023[44]. - The company has approved a borrowing limit of up to RMB 4 billion from its controlling shareholder for operational funding, with a current borrowing balance of RMB 0[22]. - The company issued a total of CNY 5 billion in short-term financing bonds on April 18, 2024, aimed at supplementing working capital and repaying bank loans[17]. - The company plans to conduct cross-border financing of up to CNY 2 billion, pending approval, to repay existing bank loans or foreign debts[21]. - The company reported a significant increase in short-term borrowings, reaching CNY 3,616,826,600.00 in Q1 2024, compared to CNY 1,300,708,300.00 in Q1 2023[39]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,655[9]. - The largest shareholder, Nanjing New Industry Investment Group Co., Ltd., held 44.13% of the shares[9]. - A total of 5,248,188 shares of restricted stock were unlocked for 396 eligible participants as part of the 2021 restricted stock incentive plan[14]. - The company plans to repurchase and cancel 1,041,972 shares of restricted stock from 32 participants who no longer meet incentive conditions, at a price of CNY 1.97 per share[15]. Business Strategy and Development - The company plans to enhance its core business and promote resource integration across business segments in 2024[7]. - The company aims to accelerate the development of its "new retail" business and advance logistics center construction and digital transformation projects[8]. - The company is collaborating with Nanjing New Industry Investment Group to develop a "medical device full-field management service platform," with an estimated R&D cost of RMB 5.8 million[23]. - The company has initiated the construction of the Fujian Tongchun Biopharmaceutical Industrial Park, which has received the necessary permits and is currently underway[24]. Research and Development - The company reported a significant increase in research and development expenses, totaling CNY 10,233,235.61, up from CNY 8,367,640.19 in Q1 2023, marking a growth of 22.3%[31]. - Research and development expenses decreased to CNY 2,030,700.00 in Q1 2024 from CNY 2,741,509.43 in Q1 2023, a reduction of 26.0%[41]. Financial Adjustments - The company updated its financial data in the prospectus for the convertible bond issuance on April 20, 2024, reflecting the latest annual report figures[12]. - The company has adjusted the annual allowance for independent directors to RMB 200,000 per person, subject to shareholder approval[27].